You May Also Like
MISSION Therapeutics is a private drug discovery company focused on elucidating and targeting the ubiquitin pathway to treat cancers and other diseases. The company develops small molecule drugs that target deubiquitylating enzymes (DUBs) involved in the DNA damage response, with the aim of inducing synthetic lethality, a powerful mechanism to selectively kill specific tumour cells. Its novel DUB technology platform integrates unique biology, screening, and chemistry capabilities to rapidly and effectively select and develop compounds targeting DUBs.
Vincere Biosciences develops small molecule therapeutics to improve mitochondrial quality. The company also develops disease-modifying therapies for Parkinson's disease. It is based in Cambridge, Massachusetts.
Mitokinin is a biotechnology company focused on developing PINK1 targeted therapies for mitochondria-associated disorders, with a particular focus on Parkinson's Disease and certain forms of mitochondrial complex I disorders.On March 2nd, 2021, Mitokini was acquired by AbbVie. Terms of the transaction were not disclosed.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.